MU Research Reactor announces FDA submission for new radioisotope process for cancer therapy
If approved, the new proprietary no-carrier-added lutetium-177 process will expand MURR’s production of cutting-edge radioisotopes used in lifesaving cancer treatments.
June 23, 2023
Contact: Uriah Orland, 573-882-6212, uriah.orland@missouri.edu
As part of the University of Missouri’s rich history of research, including the production of medical isotopes for lifesaving treatments, the MU Research Reactor (MURR) has reached a significant milestone on its path to production of no-carrier-added lutetium-177 (NCA Lu-177), a highly pure radionuclide, with the submission of a Drug Master File to the U.S. Food and Drug Administration (FDA) on May 31, 2023. Lutetium-177 is the active pharmaceutical ingredient in two targeted radioligand therapies commercially produced by Novartis.